In clinical trials, participants using these medications alongside lifestyle modifications demonstrated meaningful weight loss over 68-72 weeks, depending on the medication and dosage

References Translational Andrology and Urology (PMC) Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males (2020 review) View Source European Journal of Endocrinology (PubMed) Ipamorelin, the first selective growth hormone secretagogue (1998 preclinical pharmacology study) View Source European Journal of Anatomy Chronic in vivo Ipamorelin treatment stimulates body weight gain and growth hormone (GH) release in vitro in young female rats (2002 animal study on chronic dosing) View Source Pharmaceutical Research (PubMed) Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers (1999 Phase I clinical pharmacology study) View Source European Journal of Anatomy Three-week chronic in vivo ipamorelin treatment: no desensitization of GH release mechanisms (2002 animal study) View Source International Journal of Colorectal Disease (PubMed) Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients (2014 Phase II clinical trial) View Source Johns Hopkins Arthritis Center How to Give a Subcutaneous Injection (patient educational resource) View Source NIBSC (National Institute for Biological Standards) Peptide Handling, Dissolution & Storage Guidelines (peptide storage recommendations) View Source Creative Peptides How Long Do Peptides Last

Endocytosis and post-endocytic sorting of GLP-1R To better characterize the agonist-related differences in GLP-1R trafficking, we performed further experiments with SNAP-GLP-1R stably expressed in CHO-K1 and MIN6B1 cells
Neuroinflammation Neuroinflammation, microglia activation in response to amyloid deposition, plays a central role in the pathogenesis of AD (30)